Only Daxor’s BVA Diagnostic Was Shown to Accurately Reflect Blood Volume Compared to Inferior Surrogates
The lead investigator from Duke, Veraprapas Kittipibul M.D., commented during his award-winning presentation that surrogate markers such as “right atrial pressure and capillary wedge pressure had minimal utility to measure blood volume.” The study definitively showed the limitations of these commonly used measures of pressure to guide volume decisions, compared with Daxor’s 98% accurate BVA system.
The study, titled, ‘Blood Volume Profiles and Correlations with Pressures in Heart Failure with Impaired Renal Function,’ aimed to answer if the degree of renal impairment in heart failure patients impacts volume status, the pressure-volume relationship, and the prevalence and types of anemia.
Veraprapas Kittipibul M.D., lead investigator of the study concluded that:
- Heterogeneity in volume exists across renal function which can only be accurately measured with BVA.
- Patients with large volume expansion had worsening renal function, showing the urgent need for care.
- Pressure-volume correlation is consistently weak across renal function, showing that BVA is the right tool.
- Anemia, especially dilutional anemia, is more prevalent in worse renal function, also detectable by BVA.
“The cornerstone of heart failure care is volume management, and an accurate diagnosis of this is crucial, especially in patients at significant risk for kidney disease,” said
About
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the
Investor Relations Contact:
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
Source:
2024 GlobeNewswire, Inc., source